Psoriasis, PUVA, and skin cancer - Molecular epidemiology: The curious question of T→A transversions

Journal of Investigative Dermatology Symposium Proceedings

Volumn 4, Issue 1, 1999, Pages 11-16

  Peritz, Adam E ^a   Gasparro, Francis P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

5 methylcytosine; 8 hydroxyguanine; Melanoma; Mutation; P53; Photoadduct; Psoriasis; PUVA; Squamous cell carcinoma

Indexed keywords

5 METHYLCYTOSINE; 8 HYDROXYGUANINE; METHOXSALEN; PROTEIN P53;

ANIMAL TISSUE; CANCER RISK; CONFERENCE PAPER; GENE MUTATION; HUMAN; MELANOMA; MOUSE; NONHUMAN; PSORIASIS; PUVA; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; ULTRAVIOLET B RADIATION; VITILIGO;

EID: 0032836143     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jidsp.5640174     Document Type: Conference Paper

References (62)

1. Albino AP, Vidal MJ, McNurt NS, et al: Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 4:35-45, 1994
2. Alcalay J, Ullrich SE, Kripke ML: Local suppression of contact hypersensitivity in mice by a monofunctional psoralen plus UVA radiation. Photochem Photobiol 50:217-220, 1989
3. Bennett MA, O'Grady A, Kay EW, Leader M, Murphy GM: P53 mutations in squamous cell carcinomas from renal transplant recipients. Biochem Soc Trans 25:342-345, 1997
4. Brash DE, Rudolph JA, Simon JA, et al: A role for sunlight in skin cancer UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88:10124-10128, 1991
5. Cimino GD, Gamper HB, Isaacs ST, et al: Psoralens as photoactive probes of nucleic acid structure and function: organic chemistry, photochemistry, and biochemistry. Ann Rev Biochem 54:1151-1193, 1985
6. Deck A, Blaydes J, Hupp T, Gibbs NK: An ultraviolet action spectrum for p53 activation in vitro indicates that DNA may not be the primary chromophore. Photochem Photobiol 67:54S, 1998
7. Denisshenko MF, Chen JX, Tang M-S, Pfeifer GP: Cytosine methylation determines hot spots of DNA damage in the human p53 gene. Proc Natl Acad Sci USA 94:3893-3898, 1997
8. Dittmer D, Pati S, Zambetti C, et al: Gain of function mutations in p53. Nature Gen 4:42-46, 1993
9. Drouin R, Therrien JP: UVB-induced cyclobutane pyrimidine dimer frequency correlates with skin cancer mutational hot spots in p53. Photochem Photobiol 66:719-726, 1997
10. Eliyahu D, Raz A, Gruss P, Givol D, Oren M: Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312:646-649, 1984
11. Filipe P, Emerit I, Youssefl AA, Levy A, Carnjavski L, Freitas J, Cime de Castra JL: Oxyradical-mediated clatogenic plasma factors in psoriasis. Increases in clastogenic activity after PUVA. Photochem Photobiol 66:497-501, 1997
12. Gasparro FP: p53 in Dermatology. Arch Dermatol 134:1029-1032, 1998
13. Gasparro FP, Liao B, Foley PJ, Wang XM, McNiff JM: Psoralen photochemotherapy clinical efficacy: photomutagenicity, the role of molecular epidemiology in minimizing risks. Environ Mol Mutagenesis 31:105-112, 1998
14. Gottlieb TM, Oren M: p53 in growth control and neoplasia. Biochem Biophys Acta 1287:77-102, 1996
15. Gottlieb S, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG: Response of psoriasis to a lymphoctes-selective toxin (DAB389IL-2) suggest a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1:442-447, 1995
16. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in p53 tumor suppression gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
17. Gunther EJ, Yeasky TM, Gasparro FP, Glazer PM: Mutagenesis by 8-methoxypsoralen and 5-methylangelicin photoadducts in mouse fibroblasts: mutations at cross-linkable sites induced by of adducts as well as cross-links. Cancer Res 55:1283-1288, 1995
18. Hollstein MC, Wild CP, Bleicher F, Chutimaticwin S, Harris CC, Srivatanakul P, Montesano R: p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. Int J Cancer 53:51-55, 1993
19. Johnson R, Staiano-Coico L, Austin L, Cardinale I, Nabeya-Tsukifuji R, Krueger JG: PUVA treatment selectively induces a cell cycle block and subsequent. Apoptosis Human T-Lymphocytes Photochem Photobiol 63:566-571, 1996
20. Jonason AS, Kunala S, Price GJ, et al: Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 93:14025-14029, 1996
21. Klemm JD, Rould MA, Aurora R, Herr W, Pabo CO: Crystal structure of the October-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules. Cell 77:21-32, 1994
22. Ko LJ, Prives C: p53: puzzle and paradigm, Genes Dev 10:1054-1072, 1996
23. Kreutzer DA, Essigmann JM: Oxidized, deaminated cytosines are a source of C-> T transitions in vivo. Proc Natl Acad Sci USA 95:3578-3582, 1998
24. Kripke ML: Effects of methoxsalen plus near-ultraviolet radiation or mid-ultraviolet radiation on immunologic mechanisms. Natl Cancer Inst Monogr 66:247-251, 1984
25. Kvam E, Tyrrell RM: Induction of oxidative DNA base damage in human skin cells by UV and near visible radiation. Carcinog 18:2379-2384, 1997
26. Lane DP: Cancer. p53, guardian of the genome. Nat 358:15-16, 1992
27. Levins AJ: p53, the cellular gatekeeper for growth and division. Cell 88:323-331, 1997
28. Lewis JG, Adams D: Inflammation, oxidative DNA damage and carcinogenesis. Environ Health Perspect 76:19-27, 1987
29. Linzer DI, Levine AJ: Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52, 1979
30. McGregor J, Berkpout RJM, Rocyska M, ter Schegget J, Bavinck JNB, Brooks L, Crook T: p53 Mutations implicate sunlight in post-transplant skin cancer irrespective of human papilloma virus status. Oncogene 15:1737-1740, 1997
31. Moor ACE, Gasparro FP: Biochemical aspects of psoralen photochemotherapy. Clinics Dermatol 4:353-356, 1996
32. Nataraj AJ, Black HS, Ananthswamy HN: Signature p53 mutations at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers. Proc Natl Acad Sci USA 93:7961-7965, 1996
33. Nataraj AJ, Wolf P, Cerroni T., Ananthswamy HN: P53 mutations in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA): Relative frequency of PUVA- versus UV signature mutations. J Invest Dermatol 109:238-243, 1997
34. Okorokov AL, Ponchel P, Milner J: Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53. EMBO J 16:6008-6017, 1997
35. Palmer CM, Serafini DM, Schellhorn HE; Near ultraviolet radiation (UVA and UVB) causes a formamidopyrimidine glycosylase-dependent increase in G to T transversions. Photochem Photobiol 65:543-549, 1997
36. Parrish JA, Fitzpatrick TB, Tannenbaum L, Pathak MA: Photochemotherapy of psoriasis with oral methoxsalen and long-wave ultraviolet light. N Engl J Med 291:1207-1211, 1974
37. Pfeifer GP, Denisshenko MF: Formation and repair of DNA lesions in the p53 gene: relation to cancer mutations. Environ Mol Mutagen 31:197-205, 1998
38. Przybyszewski J, Box HC, Kulesz-Martin M: Induction of reactive oxygen species without 8-hydroxydeoxyguanosine formation in DNA of initiated mouse keratinocytes treated with 12 O tetradecanoylphorbol-13-acetate. Carcinogenesis 19:1467-1474, 1998
39. Ren ZP, Ahmadian A, Ponen F, et al: Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. Am J Pathol 150:1791-1803, 1997
40. Ren ZP, McNiff J, Gasparro FP: p53 mutations at psoralen photochemical hot spots - rare but significant events in PUVA induced skin cancers. J Invest Dermatol 112:657, 1999a
41. Ren ZP, Peritz AE, Douglass MC, McNiff J, Gasparro FP: Analysis of p53 mutations based on microdissection of tumor biopsies from psoriasis patients treated with PUVA. Photochem Photobiol 69S:29S-30S, 1999b
42. Ross PM, Yu HS. Interstrand crosslinks due to 4,5′,8′-trimethylpsoralen and near ultraviolet light in specific sequences of animal DNA. Effect of constitutive chromatin structure and of induced transcription. J Mol Biol 201:339-351, 1988
43. Rübben A, Traidl C, Baron JM, Grussendorf-Conen E:-l: Demonstration of human papillomavirus type 16-related DNA and absence of detectable p53 gene mutations in widespread cutaneous squamous cell carcinoma after oral psoralen with UV-A treatment. Arch Dermatol 132:1257-1259, 1996
44. Sage F, Bredberg A: Damage distribution and mutation spectrum: the case of 8-methoxypsoraen and UVA in mammalian cells, Mutat Res 263:217-222, 1991
45. Sagher D, Strauss B: Insertion of nucleotides opposite apurine/apyrmidinic sites in deoxyribonucleic acid during in vitra synthesis: uniqueness of adenine nucleotides. Biochem 22:4518-4526, 1983
46. Santella RM, Dharmaraja N, Gasparro FP, Monoclonal antibodies to DNA modified by 8-methoxypsoralen and ultraviolet A light. Nucl Acids Res 13:2533-2544, 1985
47. Scheffner M: Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther 78:129-139, 1998
48. Servilla KS, Burnham DK, Daynes RA: Ability of cycloporin to promote growth of transplanted ultraviolet induced tumors in mice. Transplan 44:291-295, 1987
49. Stern RS, Thibodeau LA, Kleinerman RA et al: Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med 300:809-813, 1979
50. Stern RS, Nichols KT, Väkevä LH: for the PUVA follow-up study. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N J Engl Med 336:1041-1045, 1997
51. Stern RS, Nichols KT, Väkevä LH: and the PUVA follow-up study. Oral psoralen and uitraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmclanoma skin cancer. J Natl Cancel Inst 90: 1278-1284, 1998
52. Streilein JW: Photoimmunology of non-melanoma skin cancer. Cancer Surv 26:207-217, 1996
53. Studniberg HM, Weller P: PUVA, UVB, psoriasis and nonmelanoma cancer. J Am Acad Dermatol 29:1013-1022, 1993
54. Tomassi S, Denisshenko MF, Pfeifer GP: Sunlight induces pyrimidine dimers preferentially at 5-methyleytosine bases. Cancer Res 57:4727-4730, 1997
55. Tsurudrome Y, Hirano T, Kamiya H, Yamaguchi R, Asami S, Itoh H, Kasai H: 2-hydroxyadenine, a mutagenic form of oxidative DNA damage, is not repaired by a glyocylase type mechanism in rat organs. Mat Res 408:121-127, 1998
56. Van de Kerkhof PCM, de Rooij MJM: Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response of long-tern acitretin maintenance. Br J Dermatol 136:275-278, 1997
57. Vink A A. Moodycliffe AM, Shreedhar V, Ullrich SE, Roza L, Yarosh DB, Kripke ML: The inhibition of antigen presenting activity of dendritic cells resulting from UV irradiation of murine skin is restored by in vitro photorepair of cyclobutane pyrimidine dimer. Proc Natl Acad Sci USA 94:5255-5260, 1997
58. Wang XM, McNiff JM, Klump V, Asgari M, Gasparro FP: An unexpected spectrum of p53 mutations from squamous cell carcinomas in patients treated with PUVA. Photochem Photobiol 66:294-199, 1997
59. Wang D, Kreutzer DA, Essigmann, JM: Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions. Mutat Res 400:99-115, 1998
60. Weinstock MA, Coulter S, Bates J, Bogaars HA, Larson PL, Burmer GC: Human papilloma virus and widespread cutaneous carcinoma after PUVA photochemotherapy. Anh Dermatol 131:701-704, 1995
61. Weiss J, Heine M, Arden KC, Korner B, Pilch H, Herbst R A, Jung EG: Mutation and expression of TP53 in malignant melanomas. Rec Results Cancer Res 139:137-154, 1995
62. Yun MH, Choi SJ, Shim SC, A: novel photoadduct of 4,5′,8-trimethylpsoralen and adenosine. Photochem Photobiol 55:457-460, 1992